Developer docs
API playgroundTry for free, no card

Search company profiles

Targos Molecular Pathology

Full company profile

uuid002mt7r

Namestring
Targos Molecular Pathology
Legal namestring
Targos Molecular Pathology
Websiteurl
targos-gmbh.de
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Targos Molecular Pathology is a privately held, for-profit clinical biomarker services provider founded in 2005 and headquartered in Kassel, Germany, operating with a headcount of 101–250 employees. The company positions itself as offering a highly standardized environment for clinical biomarker research, development, and application, serving as a specialized services partner within the global histopathology and tissue diagnostics sector.

Its primary customer base consists of hospitals and diagnostic laboratories worldwide that utilize histopathology services for tissue analysis, disease identification, and characterization in clinical settings. Targos is identified as a key player in the global histopathology services market alongside competitors including TPL Path Labs, UNILABS, and Sonic Healthcare Limited. The addressable market is projected to grow from approximately US$23.89 billion in 2021 to US$35.19 billion by 2028 at a 5.7% CAGR, with growth driven by increasing cancer prevalence, demand for personalized medicine, and the adoption of digital pathology platforms, AI tools, and automated tissue processing technologies.

Detailed information regarding Targos' specific product portfolio, underlying technology stack, pricing model, go-to-market motion, geographic footprint beyond Germany, ownership structure, funding history, and named customers is not disclosed in the available source material. Source attribution is limited to a single market-research reference, and no company-level operational disclosures (revenue, M&A, leadership, certifications, or product launches) are available to triangulate further.

Short descriptiontext

Targos Molecular Pathology, founded in 2005 and headquartered in Kassel, Germany, provides standardized clinical biomarker research, development, and application services for hospitals and diagnostic laboratories worldwide in the histopathology services sector.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKassel, Germany
HQ citystring
Kassel
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
molecular pathology services, clinical biomarker research, histopathology services, tissue diagnostics, biomarker development
Industry3 codes
PRIMARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Pathology Services
Social media profiles1 record
Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Targos Molecular Pathology provides a highly standardized environment for clinical biomarker research, development, and application. The company operates in the tissue diagnostics sector, offering histopathology and molecular pathology services to support disease identification, characterization, and personalized medicine initiatives for hospitals and diagnostic laboratories worldwide.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product and services information available for Targos Molecular Pathology in the provided source data.

Product and service1 record
1Clinical Biomarker Research and Development Services
CategoryMolecular Pathology Services
Description

Highly standardized environment for clinical biomarker research, development, and application supporting tissue-based diagnostic services for disease identification and characterization. Targeted at hospitals and diagnostic laboratories.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

Global medical diagnostics and pathology incumbent listed in the same market report as Targos. Offers anatomic and molecular pathology services across many geographies at significantly larger scale.

TypeDirect peer
Description

European-headquartered clinical diagnostics and pathology services provider explicitly named alongside Targos in the same histopathology market report. Overlaps directly in anatomic pathology and biomarker services for hospitals and clinical trial sponsors.

TypeDirect peer
Description

Central laboratory and biomarker services provider for clinical trials, jointly backed by IQVIA. Directly comparable to Targos's standardized biomarker research and development environment for pharma sponsors.

TypeDirect peer
Description

US-based specialty oncology / molecular pathology laboratory serving hospitals, pharma and clinical trial sponsors with biomarker assays. Comparable business model targeting the same oncology clinical trial customer base.

TypeBroad incumbent
Description

Large European medical diagnostics services provider offering clinical laboratory and pathology services including histology and molecular diagnostics. Headquartered in Germany-adjacent Europe, directly relevant as a regional competitor.

TypeDirect peer
Description

European clinical diagnostics and specialty pathology network with strong central lab and biomarker capabilities. Competes with Targos for pharma and hospital pathology work across Europe.

TypeDirect peer
Description

Provides biospecimens and molecular pathology services including IHC, multiplex immunofluorescence, ISH, and digital pathology — directly comparable to Targos's biomarker and tissue-based diagnostics offering, especially for clinical trial sponsors.

TypeBroad incumbent
Description

Major central laboratory offering biomarker, anatomic pathology and companion diagnostic services to global clinical trial sponsors. A scaled competitor for biomarker workflow work that Targos also targets.

TypeDirect peer
Description

Histopathology services provider named alongside Targos as a key player in the global histopathology services market. Direct overlap in tissue-based diagnostic and anatomic pathology services.

TypeEmerging player
Description

Specialized anatomic and molecular pathology laboratory serving community hospitals and oncology practices. Comparable specialty pathology focus though at a smaller scale and US-centric footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Targos Molecular Pathology

Molecular Pathology Servicestargos-gmbh.de

Targos Molecular Pathology, founded in 2005 and headquartered in Kassel, Germany, provides standardized clinical biomarker research, development, and application services for hospitals and diagnostic laboratories worldwide in the histopathology services sector.

What Targos Molecular Pathology does

Targos Molecular Pathology is a privately held, for-profit clinical biomarker services provider founded in 2005 and headquartered in Kassel, Germany, operating with a headcount of 101–250 employees. The company positions itself as offering a highly standardized environment for clinical biomarker research, development, and application, serving as a specialized services partner within the global histopathology and tissue diagnostics sector.

Its primary customer base consists of hospitals and diagnostic laboratories worldwide that utilize histopathology services for tissue analysis, disease identification, and characterization in clinical settings. Targos is identified as a key player in the global histopathology services market alongside competitors including TPL Path Labs, UNILABS, and Sonic Healthcare Limited. The addressable market is projected to grow from approximately US$23.89 billion in 2021 to US$35.19 billion by 2028 at a 5.7% CAGR, with growth driven by increasing cancer prevalence, demand for personalized medicine, and the adoption of digital pathology platforms, AI tools, and automated tissue processing technologies.

Detailed information regarding Targos' specific product portfolio, underlying technology stack, pricing model, go-to-market motion, geographic footprint beyond Germany, ownership structure, funding history, and named customers is not disclosed in the available source material. Source attribution is limited to a single market-research reference, and no company-level operational disclosures (revenue, M&A, leadership, certifications, or product launches) are available to triangulate further.

Targos Molecular Pathology firmographics

Firmographics
Name
Targos Molecular Pathology
Legal name
Targos Molecular Pathology
Website
https://targos-gmbh.de
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Targos Molecular Pathology, founded in 2005 and headquartered in Kassel, Germany, provides standardized clinical biomarker research, development, and application services for hospitals and diagnostic laboratories worldwide in the histopathology services sector.
Ownership category
akta.pro rank

Targos Molecular Pathology industry classification

Industry
Product category
Molecular Pathology Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular pathology services
  • Clinical biomarker research
  • Histopathology services
  • Tissue diagnostics
  • Biomarker development

Where Targos Molecular Pathology is headquartered

Location

Headquarters

HQ city
Kassel
HQ country
Germany
HQ region
Europe

Markets served

Targos Molecular Pathology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Targos Molecular Pathology product offering

Product offering

Core offering

Targos Molecular Pathology provides a highly standardized environment for clinical biomarker research, development, and application. The company operates in the tissue diagnostics sector, offering histopathology and molecular pathology services to support disease identification, characterization, and personalized medicine initiatives for hospitals and diagnostic laboratories worldwide.

Product overview

No product and services information available for Targos Molecular Pathology in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Biomarker Research and Development Services Highly standardized environment for clinical biomarker research, development, and application supporting tissue-based diagnostic services for disease identification and characterization. Targeted at hospitals and diagnostic laboratories.

Companies that use Targos Molecular Pathology

Customer profile

Segments1 record

Ideal customer profiles1 record

Targos Molecular Pathology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Targos Molecular Pathology partnerships and signals

Strategic signal

Scale indicators1 record

Targos Molecular Pathology competitors and assessment

Company assessment

Broad incumbents

  • Sonic Healthcare Limited: Global medical diagnostics and pathology incumbent listed in the same market report as Targos. Offers anatomic and molecular pathology services across many geographies at significantly larger scale.
  • SYNLAB Group: Large European medical diagnostics services provider offering clinical laboratory and pathology services including histology and molecular diagnostics. Headquartered in Germany-adjacent Europe, directly relevant as a regional competitor.
  • LabCorp Drug Development (now Fortrea): Major central laboratory offering biomarker, anatomic pathology and companion diagnostic services to global clinical trial sponsors. A scaled competitor for biomarker workflow work that Targos also targets.

Direct peers

  • UNILABS: European-headquartered clinical diagnostics and pathology services provider explicitly named alongside Targos in the same histopathology market report. Overlaps directly in anatomic pathology and biomarker services for hospitals and clinical trial sponsors.
  • Q² Solutions: Central laboratory and biomarker services provider for clinical trials, jointly backed by IQVIA. Directly comparable to Targos's standardized biomarker research and development environment for pharma sponsors.
  • NeoGenomics: US-based specialty oncology / molecular pathology laboratory serving hospitals, pharma and clinical trial sponsors with biomarker assays. Comparable business model targeting the same oncology clinical trial customer base.
  • Cerba HealthCare: European clinical diagnostics and specialty pathology network with strong central lab and biomarker capabilities. Competes with Targos for pharma and hospital pathology work across Europe.
  • Discovery Life Sciences: Provides biospecimens and molecular pathology services including IHC, multiplex immunofluorescence, ISH, and digital pathology — directly comparable to Targos's biomarker and tissue-based diagnostics offering, especially for clinical trial sponsors.
  • TPL Path Labs: Histopathology services provider named alongside Targos as a key player in the global histopathology services market. Direct overlap in tissue-based diagnostic and anatomic pathology services.

Emerging players

  • Histo-Path Laboratories / Centrex Diagnostics: Specialized anatomic and molecular pathology laboratory serving community hospitals and oncology practices. Comparable specialty pathology focus though at a smaller scale and US-centric footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Targos Molecular Pathology social profiles

Digital presence

Targos Molecular Pathology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Targos Molecular Pathology leadership team

Management profile

Number of profiles

Targos Molecular Pathology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Targos Molecular Pathology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Targos Molecular Pathology

What does Targos Molecular Pathology do?

Targos Molecular Pathology provides a highly standardized environment for clinical biomarker research, development, and application. The company operates in the tissue diagnostics sector, offering histopathology and molecular pathology services to support disease identification, characterization, and personalized medicine initiatives for hospitals and diagnostic laboratories worldwide.

When was Targos Molecular Pathology founded?

Targos Molecular Pathology was founded in 2005. It employs 1 to 10 people.

Where is Targos Molecular Pathology based?

Targos Molecular Pathology is headquartered in Kassel, Germany, in the Europe region.

Who are Targos Molecular Pathology's main competitors?

Broad incumbents on record are Sonic Healthcare Limited, SYNLAB Group and LabCorp Drug Development (now Fortrea). Direct peers are UNILABS, Q² Solutions, NeoGenomics, Cerba HealthCare, Discovery Life Sciences and TPL Path Labs. Histo-Path Laboratories / Centrex Diagnostics is listed as an emerging player.

Does Targos Molecular Pathology have an API?

No public API is recorded for Targos Molecular Pathology.

What industry is Targos Molecular Pathology in?

Targos Molecular Pathology's product category is Molecular Pathology Services. Its primary akta.pro industry code is HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support), with a secondary code of HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals